Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer
Background: Anlotinib is a small molecular multi-targeting tyrosine kinase inhibitor. Growing evidence indicates that treatment efficacy, and toxicity varies considerably between individuals. Therefore, this study aimed to investigate the relationship between cytochrome P450 (CYP450) gene polymorphi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.918219/full |
| _version_ | 1811241575611629568 |
|---|---|
| author | Tingfei Tan Gongwei Han Ziwei Cheng Jiemei Jiang Li Zhang Zitong Xia Xinmeng Wang Quan Xia |
| author_facet | Tingfei Tan Gongwei Han Ziwei Cheng Jiemei Jiang Li Zhang Zitong Xia Xinmeng Wang Quan Xia |
| author_sort | Tingfei Tan |
| collection | DOAJ |
| description | Background: Anlotinib is a small molecular multi-targeting tyrosine kinase inhibitor. Growing evidence indicates that treatment efficacy, and toxicity varies considerably between individuals. Therefore, this study aimed to investigate the relationship between cytochrome P450 (CYP450) gene polymorphisms, drug concentrations, and their adverse reactions in anlotinib-treated patients with lung cancer.Methods: We enrolled 139 patients with lung cancer, treated with anlotinib. Twenty loci in the following five genes of the CYP450 family were genotyped: CYP450 family 3 subfamily A member 5 (CYP3A5), 3 subfamily A member 4 (CYP3A4), 2 subfamily C member 9 (CYP2C9), 2 subfamily C member 19 (CYP2C19), and 1 subfamily A member 2 (CYP1A2). Data on adverse reactions were collected from patients, and plasma anlotinib concentrations were measured.Results: There were significant variances in plasma trough concentration (3.95–52.88 ng/ml) and peak plasma concentration (11.53–42.8 ng/ml) following administration of 8 mg anlotinib. Additionally, there were significant differences in the plasma trough concentration (5.65–81.89 ng/ml) and peak plasma concentration (18.01–107.18 ng/ml) following administration of 12 mg anlotinib. Furthermore, for CYP2C19-rs3814637, the peak plasma concentrations of mutant allele T carriers (TT+CT) were significantly higher than those of wildtypes (CC). For CYP2C19-rs11568732, the peak plasma concentrations of the mutant allele G carriers (GT+GG) were significantly higher than those of the wild-type (TT). More importantly, the incidence rates of hypertension and hemoptysis (peripheral lung cancer) with TT+CT in rs3814637 and GT+GG in rs11568732 were significantly higher than those with CC and TT.Conclusions: The plasma trough and peak concentrations varied significantly for both 8 and 12 mg of anlotinib. Single-nucleotide polymorphisms in CYP2C19 are significantly associated with hypertension, hemoptysis, and anlotinib peak concentrations. Polymorphisms in CYP450 may explain inter-individual differences in anlotinib-related adverse reactions. |
| first_indexed | 2024-04-12T13:38:12Z |
| format | Article |
| id | doaj.art-4faa9a0a35214a09882b3318df8c59c8 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T13:38:12Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-4faa9a0a35214a09882b3318df8c59c82022-12-22T03:30:56ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-06-011310.3389/fphar.2022.918219918219Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung CancerTingfei Tan0Gongwei Han1Ziwei Cheng2Jiemei Jiang3Li Zhang4Zitong Xia5Xinmeng Wang6Quan Xia7Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaSchool of Pharmacy, Anhui Medical University, Hefei, ChinaSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei, ChinaDepartment of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Pharmacy, The Second Affiliated Hospital of Bengbu Medical College, Bengbu, ChinaSchool of Pharmacy, Anhui Medical University, Hefei, ChinaDepartment of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaBackground: Anlotinib is a small molecular multi-targeting tyrosine kinase inhibitor. Growing evidence indicates that treatment efficacy, and toxicity varies considerably between individuals. Therefore, this study aimed to investigate the relationship between cytochrome P450 (CYP450) gene polymorphisms, drug concentrations, and their adverse reactions in anlotinib-treated patients with lung cancer.Methods: We enrolled 139 patients with lung cancer, treated with anlotinib. Twenty loci in the following five genes of the CYP450 family were genotyped: CYP450 family 3 subfamily A member 5 (CYP3A5), 3 subfamily A member 4 (CYP3A4), 2 subfamily C member 9 (CYP2C9), 2 subfamily C member 19 (CYP2C19), and 1 subfamily A member 2 (CYP1A2). Data on adverse reactions were collected from patients, and plasma anlotinib concentrations were measured.Results: There were significant variances in plasma trough concentration (3.95–52.88 ng/ml) and peak plasma concentration (11.53–42.8 ng/ml) following administration of 8 mg anlotinib. Additionally, there were significant differences in the plasma trough concentration (5.65–81.89 ng/ml) and peak plasma concentration (18.01–107.18 ng/ml) following administration of 12 mg anlotinib. Furthermore, for CYP2C19-rs3814637, the peak plasma concentrations of mutant allele T carriers (TT+CT) were significantly higher than those of wildtypes (CC). For CYP2C19-rs11568732, the peak plasma concentrations of the mutant allele G carriers (GT+GG) were significantly higher than those of the wild-type (TT). More importantly, the incidence rates of hypertension and hemoptysis (peripheral lung cancer) with TT+CT in rs3814637 and GT+GG in rs11568732 were significantly higher than those with CC and TT.Conclusions: The plasma trough and peak concentrations varied significantly for both 8 and 12 mg of anlotinib. Single-nucleotide polymorphisms in CYP2C19 are significantly associated with hypertension, hemoptysis, and anlotinib peak concentrations. Polymorphisms in CYP450 may explain inter-individual differences in anlotinib-related adverse reactions.https://www.frontiersin.org/articles/10.3389/fphar.2022.918219/fullanlotiniblung cancerCYP450 gene polymorphismsplasma concentrationadverse reactions |
| spellingShingle | Tingfei Tan Gongwei Han Ziwei Cheng Jiemei Jiang Li Zhang Zitong Xia Xinmeng Wang Quan Xia Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer Frontiers in Pharmacology anlotinib lung cancer CYP450 gene polymorphisms plasma concentration adverse reactions |
| title | Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer |
| title_full | Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer |
| title_fullStr | Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer |
| title_full_unstemmed | Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer |
| title_short | Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer |
| title_sort | genetic polymorphisms in cyp2c19 cause changes in plasma levels and adverse reactions to anlotinib in chinese patients with lung cancer |
| topic | anlotinib lung cancer CYP450 gene polymorphisms plasma concentration adverse reactions |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.918219/full |
| work_keys_str_mv | AT tingfeitan geneticpolymorphismsincyp2c19causechangesinplasmalevelsandadversereactionstoanlotinibinchinesepatientswithlungcancer AT gongweihan geneticpolymorphismsincyp2c19causechangesinplasmalevelsandadversereactionstoanlotinibinchinesepatientswithlungcancer AT ziweicheng geneticpolymorphismsincyp2c19causechangesinplasmalevelsandadversereactionstoanlotinibinchinesepatientswithlungcancer AT jiemeijiang geneticpolymorphismsincyp2c19causechangesinplasmalevelsandadversereactionstoanlotinibinchinesepatientswithlungcancer AT lizhang geneticpolymorphismsincyp2c19causechangesinplasmalevelsandadversereactionstoanlotinibinchinesepatientswithlungcancer AT zitongxia geneticpolymorphismsincyp2c19causechangesinplasmalevelsandadversereactionstoanlotinibinchinesepatientswithlungcancer AT xinmengwang geneticpolymorphismsincyp2c19causechangesinplasmalevelsandadversereactionstoanlotinibinchinesepatientswithlungcancer AT quanxia geneticpolymorphismsincyp2c19causechangesinplasmalevelsandadversereactionstoanlotinibinchinesepatientswithlungcancer |